publication . Article . 2013

Hyperimmune IV Immunoglobulin Treatment

Ivan Hung; Kelvin K. W. To; Cheuk-Kwong Lee; Kar-Lung Lee; Wing-Wa Yan; Kenny Chan; Wai-Ming Chan; Chun-Wai Ngai; K I Law; Fu-Loi Chow; ...
Closed Access
  • Published: 28 Feb 2013 Journal: Chest, volume 144, pages 464-473 (issn: 0012-3692, Copyright policy)
  • Publisher: Elsevier BV
Background Experience from influenza pandemics suggested that convalescent plasma treatment given within 4 to 5 days of symptom onset might be beneficial. However, robust treatment data are lacking. Methods This is a multicenter, prospective, double-blind, randomized controlled trial. Convalescent plasma from patients who recovered from the 2009 pandemic influenza A(H1N1) (A[H1N1]) infection was fractionated to hyperimmune IV immunoglobulin (H-IVIG) by CSL Biotherapies (now BioCSL). Patients with severe A(H1N1) infection on standard antiviral treatment requiring intensive care and ventilatory support were randomized to receive H-IVIG or normal IV immunoglobulin ...
Persistent Identifiers
free text keywords: Cardiology and Cardiovascular Medicine, Critical Care and Intensive Care Medicine, Pulmonary and Respiratory Medicine, Intensive care, Randomized controlled trial, law.invention, law, Internal medicine, medicine.medical_specialty, medicine, Surgery, Respiratory system, business.industry, business, Prospective cohort study, Antibody, biology.protein, biology, Influenza A virus, medicine.disease_cause, Adverse effect, Viral load
Related Organizations
Any information missing or wrong?Report an Issue